One of the big lies posted elsewhere is the claim

One of the big lies posted elsewhere is the claim that CTIX is totally dependent on Prurisol.

This is absolutely untrue. First, let me say that the results thus far in the Prurisol clinical trial have been very encouraging, and I think that it is extremely likely that Prurisol will emerge as at the very least a viable drug, and very possibly the first-line treatment of choice for psoriasis.

But, in the very unlikely event that Prurisol suddenly has a safety or efficacy issue, there are two other drugs, Kevetrin (cancer) and Brilacidin (new class of antibiotics with powerful anti-inflammatory characteristics) to fall back on.

Very few small biotechs have more than one new drug in clinical trials. To have 3 in clinical trials (and in the case of Brilacidin, various formulations in clinical trials for several different applications) is very unusual. This gives a level of diversification that few small companies have. A market cap of around 150 million for this stock is absurd, and in my opinion (and in my investing strategy) is a huge opportunity.